نمایش پرونده ساده آیتم

dc.contributor.authorQamsari, ES
dc.contributor.authorNourazarian, A
dc.contributor.authorBagheri, S
dc.contributor.authorMotallebnezhad, M
dc.date.accessioned2018-08-26T05:37:50Z
dc.date.available2018-08-26T05:37:50Z
dc.date.issued2016
dc.identifier.urihttp://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/39947
dc.description.abstractSince their discovery in 1940, it has been well established that gangliosides are associated with a number of biological pathways and cellular processes such as growth, differentiation and toxin uptake. Gangliosides are glycosphingolipids containing neuraminic acid which are expressed on the plasma membrane of cells particularly in the nervous system. Heterogeneity and structural variation in the carbohydrate chains of gangliosides contributes to unique features of each of these molecules. Thirty five years ago it was discovered that aberrant glycosylation occurs in a variety of human cancers, including aberrant glycosylation of gangliosides. Ganglioside expression in terms of quality and quantity varies in different cancers and different roles may be played. Gangliosides, by affecting the immune system, including esxpression of cytokines and adhesion molecules, may inhibit anti-tumor mechanisms, as well as having direct impact on angiogenesis, cell movement and metastasis. It should be noted that different kinds of gangliosides do not all act by the same mechanisms.
dc.language.isoEnglish
dc.relation.ispartofAsian Pacific journal of cancer prevention : APJCP
dc.subjectAnimals
dc.subjectGangliosides
dc.subjectHumans
dc.subjectNeoplasms
dc.titleGanglioside as a Therapy Target in Various Types of Cancer.
dc.typearticle
dc.citation.volume17
dc.citation.issue4
dc.citation.spage1643
dc.citation.epage7
dc.citation.indexPubmed


فایلهای درون آیتم

فایلهاسایزفرمتنمایش

هیچ فایل مرتبطی وجود ندارد

این آیتم در مجموعه های زیر مشاهده می شود

نمایش پرونده ساده آیتم